Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIO-101 in Dry Eye Disease with Autoimmune Disease
NCT05629364Phase 2Terminated
- Sponsor
- Kiora Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KIO-101 in dry eye disease (DED) (3 arms), sponsored by Kiora Pharmaceuticals. Primary endpoint: Change in Schirmer's 1 Test at 12 weeks. Started Mar 2023; status: terminated.
02
Drugs
KIO-101
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05629364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629364.